Pelthos expands ZELSUVMI coverage to 127 million lives
Pelthos Therapeutics (NYSE American:PTHS) expanded ZELSUVMI's formulary coverage to 127 million lives, adding a major PBM covering 24 million and a regional plan covering 3 million. The treatment, launched in July 2025, now reaches 69% of the commercial market and over 70 million Medicaid lives. ZELSUVMI is approved for molluscum contagiosum in patients aged 1+ years.
How this was made
The 30-second read
Why it matters
The new formulary agreements remove prior‑authorization barriers, expanding patient access and likely improving revenue forecasts.
Market read
First‑time disclosure of a large formulary expansion for a niche dermatology product, creating a potential catalyst for the stock.
What to watch
Potential pricing pressure from Medicaid and payer negotiations could offset coverage benefits
Background
Pelthos Therapeutics' ZELSUVMI is a nitric‑oxide releasing gel for molluscum contagiosum, launched in July 2025 and recently received Novel Drug designation.
Ticker impact
Pelthos Therapeutics announced new formulary coverage for ZELSUVMI expanding to 127 million lives, a first‑time disclosure of the deal.
likely upward pressure as investors price in higher revenue potential
Coverage of 127 M lives represents 69% of the commercial market, a material increase in addressable patients.
Market effects
broader dermatology/skin‑care biotech sector may see heightened interest in similar topical therapies
U.S. specialty pharma market gains a new covered product, modest regional effect
limited to U.S. market where coverage was granted
Counterpoint
Coverage may not translate into immediate sales if reimbursement rates are low or if competitors launch alternatives
Key entities
- companyPelthos Therapeutics Inc.
Developer of ZELSUVMI, a topical treatment for molluscum contagiosum.
- productZELSUVMI
Topical gel (berdazimer) indicated for molluscum contagiosum.
